Hey, everyone! I took a couple of weeks off from the

New Post Public Reply Private Reply Replies (2) Message Board
Buildit
510
Hey, everyone!

I took a couple of weeks off from the board, but I got caught up on all the messages last night.

I will be up front. I have been frustrated with the general tone of our board at times lately, particularly since the last two deal announcements. And I believe it may have harmed our collective goal, as some of the best news we have had in a long time has been released since then, and some new eyes (and potential investment capital) may have taken a gander our way for the first time in a while.

I sent out PMs to a bunch of other posters last night, many of which have reduced or ceased their postings as well in the past month or so, just to sanity check my perception of the board. Not everyone has responded yet, but enough have echoed my thoughts that I feel comfortable posting this message now.


To be clear I am not knocking anyone’s right to say what they want on this board. And I do not want to paper over mistakes made by Joe and others in the past year or two or discourage the group from acting as a check on the system.

However, this is our current reality, and these are the current options that are available to Joe and to us. If we are all truly shareholders here, we should all want the overall impression that is painted on this board to be a net-positive one. Because what we need most of all in this stock is new investors. And, for now, these investors are not funds and managers, they are mostly just regular individuals like ourselves.


After new investors read a PR or an article or view an interview about a stock like GNBT, where do they go? There is no analyst coverage. There are no professionals from investment firms “covering” this stock. In cases like this, potential investors come to the boards to see what people who are involved in the stock think about it. First they might go to YMB. Oh boy… great first impression. But after they get disgusted with that, maybe they end up here. Frankly, for the last few weeks, since our latest positive news, IH has not looked much more enticing than YMB at times.

I am not trying to say that Joe did not make mistakes or that maybe a different path should not have been chosen at certain points along the way. This has been a rough road. Some of those bumps and potholes could have been repaired or avoided, but some were thrown right in front of us.

I am also not suggesting you swallow your thoughts and concerns. But instead think before you post your comments (especially on days when new investors might be checking us out) if there is a better avenue down which you could pursue them. How many of you have contacted Joe about your recently voiced concerns on dilution? Or Bintai and its partners? I suggest you all do that at least once, if you are comfortable with that approach. It is a unique situation when your CEO is as open as Joe is, and it can be one of the quickest ways to allay your frustrations or get clarification. If you are not able to do that or are not comfortable with that approach, send someone a PM and see if they share your concern and can clarify or will follow up with Joe.


Like it or not, this group is a surrogate for our investment due to the depth of our experience with this company. What we post here has an air of knowledge and authority to new investors, whether we like it or not. There is so much knowledge here that can be shared with potential investors, if we can only encourage them to engage. So before we post (again, especially when good times are trying to bubble up), maybe we can ask ourselves a few questions:

- Is my post unproductively negative? Instead of reinforcing a negative feedback loop, is there a way I could have the same communication and maybe get better feedback by phrasing my comment a different way?

- Is my post liable to lead to no good end other than to turn people off on our collective investment? (We've all vented occasionally. But this should not be the main area of content on our board.)

- Is my post really regarding something that is in the past and that no one can do anything about? Or has something become so personal that I need to deal with it in a different way?

- Should I take this offline to a PM w someone who usually knows about this topic?

- Should I do more homework or call/email Joe?

- Maybe most important: Is a solution to my issue in the works, and I just need to be patient? Sometimes, as this morning has shown, silence can be an acceptable option.


Once again, I know not everything is positive in Generex/NGIO world. There is much frustration built up over the past year or so, and I share that with all of you.

I also know how exhausting this has been for all of us, how much effort has been put in by so many people here, and how this board has been unnecessarily and unfairly personal at times. And many of the events, SEC docs, technical concepts, etc. of the past year or two have been challenging for those of us that are not professional investors.

But I also know that our collective investment is in a better position now than it has been in a long time. So let’s remember that, as we discuss our questions, ideas, and concerns on this board, potential investors are watching. Let’s be up front, curious, and rigorous. But in the interest of all of our investments, let’s be constructive.

Sorry for anyone I may have offended or appeared to single out here. That is certainly not my objective…

I remain as positive as I have been in a long time (much more so than when I was a frequent "venter" over the summer!). And I look forward to the pieces coming into place over the next few months.

Thanks for your consideration, and have a great week, everyone!

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SHOPLINE's Pitch Day: 14 Brands in the Spotlight

Updated Category News Views 87

SHOPLINE's Los Angeles Event Highlights Emerging Brands Flip the calendar back to October 1, and you'll find me soaking in the scene at the sprawling halls of SHOPLINE and Plug and Play’s latest event. This wasn’t your run-of-the-mill networking affair; it was a caffeine-fueled, adrenaline-pumping showcase of 14 up-and-coming consumer brands. Now, if there's one thing...

Continue Reading
Unum Group Faces Investigation Amid $419.7M Net Loss

Updated Category News Views 38

Troubling Times for Unum Group Investors Alright, folks, let’s get down to brass tacks: Unum Group (NYSE: UNM) is swimming upstream, and not in any leisurely, salmon-like sense. Their third-quarter report revealed a whopping $419.7 million net loss—something that can unsettle even the steadiest ship in the murky waters of the market. Pair that with an SEC...

Continue Reading
Gastops and Anschütz: Boosting Canada's Submarine Project

Updated Category News Views 62

New Partnership on the Horizon for Canada’s Submarines In today's world, where defense contracts become the dance of global players, Gastops and Anschütz have clasped hands to join the orchestra. The news blew in from EURONAVAL 2026, where these two powerhouses in condition monitoring and missile systems, respectively, inked a fresh Memorandum of Understanding to back...

Continue Reading
MegazoneSoft Grabs Dual Google Cloud Competencies

Updated Category News Views 43

Doubling Down on Google Cloud Glory Imagine scoring not one, but two top-tier achievements in the fast and furious tech space. That's exactly what MegazoneSoft, an arm of MegazoneCloud, just did. These folks snagged Google Cloud Advanced Competencies in both Gemini Enterprise and Artificial Intelligence. You gotta tip your hat to a company that tackles the digital jungle...

Continue Reading
Maple Leaf Foods' Q3 Results: Growth Amidst Inflation

Updated Category News Views 50

Navigating Inflationary Waters: A Maple Leaf Foods Update Seeing Maple Leaf Foods (TSX: MFI) push through a tough inflationary landscape with a 15.4% rise in EBITDA would make any seasoned investor nod in respect. They've gone from last year's $111.7 million to a hefty $129 million in Q3 2026. What's more, their EBITDA margin climbed to 12.5%, up 140 basis points from...

Continue Reading
Verismo's SynKIR™-310 Shows Promise in Phase 1 Trials

Updated Category News Views 42

KIR-CAR: A Fresh Take on Cancer Treatment So, Verismo Therapeutics is at it again with their KIR-CAR platform. They're set to present interim data at this year's ASH Annual Meeting. To all those following B-cell non-Hodgkin Lymphoma (B-NHL) treatments, pay attention. SynKIR™-310, a CD19-targeted therapy, is showing some real promise. The science behind this is like...

Continue Reading
Bascom's $30.8M Vegas Refi Amid Market Hurdles

Updated Category News Views 111

Diving into the Vegas Real Estate Scene Alright, folks, let's roll up our sleeves and talk about something that's got my attention—Bascom Group's recent $30.8 million refinance of the Gateway Villas Apartments in Las Vegas. This ain't just another vanilla transaction in the back pages of some real estate journal. It's a play that screams strategy, especially in a world...

Continue Reading
AutoFlight's Game-Changing 5-eVTOL Formation Flight

Updated Category News Views 25

Pioneering the Skies: AutoFlight's Latest Feat Now, ever seen a flock of eVTOLs carving up the sky without anyone at the controls? Yep, AutoFlight just pulled that off. This isn't your everyday aviation stunt; it's a world-first five-eVTOL formation flight—fully autonomous, mind you—staged across the scenic backdrop of Kunshan, China. This was more than just a...

Continue Reading
Gold Royalty's Stellar Q3: Cash Surge, Growth Ahead

Updated Category News Views 30

Gold Royalty's Unstoppable Momentum in 2026 Gold Royalty Corp. (NYSE:GROY) ain't just any player on the block; they're shakin' up the room with some jaw-dropping numbers. This Vancouver-based beast isn't just surfing the gold waves, it's riding a tsunami with all sails hoisted. As of September 30, 2026, they're shouting from the rooftops about a third quarter that's set...

Continue Reading
VeriSilicon's GCNanoOptimaV Transforms Wearable Tech

Updated Category News Views 41

Revving Up Wearables with Next-Gen Graphics Well, folks, VeriSilicon's at it again, rolling out some cutting-edge technology in the form of their spanking new GCNanoOptimaV GPU IP. If you're scratching your head wondering what this means for your wrist-bound gadgets, hang tight—I'm about to spell it out. Architectural Innovations: Striking the Balance Here's the scoop...

Continue Reading

Top 5 Most Recently Viewed Articles

Moroccan Stocks Close Slightly Lower Despite Energy Gains

Updated Category News Views 162

Moroccan Stock Market Overview The Moroccan stock market presented a mixed closing with slight downturns noted in key sectors. The Moroccan All Shares index dipped by 0.01% as various sectors faced challenges, notably the Real Estate, Utilities, and Holding Companies. Market Performance and Sector Analysis In the heart of Casablanca's trading activities, the Moroccan All...

Continue Reading
emeis Exceeds Expectations with Strong Growth Strategies

Updated Category News Views 262

emeis Reports Strong Guidance Exceeding Expectations In a landscape where businesses continuously adapt to changing times, emeis is making significant strides in its operational performance. This report highlights how the company surpassed its guidance, indicating a robust trajectory towards growth and customer satisfaction. Improving Resident Satisfaction and Performance...

Continue Reading
UAW Calls for Strike Authorization at Stellantis Amidst Disputes

Updated Category News Views 58

The United Auto Workers (UAW) called it back in 2024—a looming strike against Stellantis was brewing. Tensions boiled over as UAW President Shawn Fain fired off a letter to local chapters, raising alarms about what they saw as serious contract breaches by the French-Italian auto giant. Contract Violations: A Powder Keg Ready to Explode? Fain wasn't just blowing smoke;...

Continue Reading
AlphaMedix Data Shows Promising Results for Rare Cancer Treatment

Updated Category News Views 212

Recent Advancements in Cancer Therapy with AlphaMedix Recent data from the AlphaMedix™ study highlights remarkable potential in the realm of oncology, particularly for patients battling gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This innovative treatment brings a fresh perspective to cancer therapy, specifically for those who face challenging medical...

Continue Reading
Snowflake's Earnings Report: An In-Depth Analysis of SNOW

Updated Category News Views 379

Understanding Snowflake's Recent Q3 Earnings Snowflake Inc (NYSE: SNOW) recently released its financial results for the third quarter, and the market has responded with noticeable fluctuations in stock price. The data cloud company is known for its innovative approach to data management and storage, and its earnings report shines a spotlight on various critical metrics...

Continue Reading